Skip to main content

Multiple System Atrophy

13
Pipeline Programs
14
Companies
18
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
8
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Gene Therapy
150%
+ 17 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Lundbeck
LundbeckDenmark - Copenhagen
3 programs
2
1
AmlenetugPhase 31 trial
Lu AF82422Phase 21 trial
rasagiline mesylatePhase 2
Active Trials
NCT05104476Active Not Recruiting64Est. Mar 2028
NCT06706622Active Not Recruiting401Est. Oct 2029
Rare Disease Therapeutics
1 program
1
RifampicinPhase 31 trial
Active Trials
NCT01287221Terminated100Est. Jan 2013
Alterity Therapeutics
Alterity TherapeuticsAustralia - Melbourne
3 programs
2
ATH434Phase 21 trial
ATH434 dose level 1Phase 21 trial
ATH434N/A1 trial
Active Trials
NCT07531433Available
NCT05864365Completed10Est. Feb 2025
NCT05109091Completed77Est. Nov 2024
Tiziana Life Sciences
Tiziana Life SciencesLONDON, ENGLAND, United Kingdom
1 program
1
Foralumab NasalPhase 21 trial
Active Trials
NCT06868628Recruiting5Est. Apr 2027
Zambon
ZambonItaly - Bresso
1 program
1
Safinamide MethanesulfonatePhase 21 trial
Active Trials
NCT03753763Completed49Est. Jan 2021
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
TAK-341Phase 2
Yoda Therapeutics
Yoda TherapeuticsTaiwan - Taipei
1 program
1
YA-101Phase 21 trial
Active Trials
NCT06848231Recruiting75Est. Dec 2026
Corestemchemon
CorestemchemonKorea - Seongnam
2 programs
1
CS10BR05Phase 11 trial
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)N/A1 trial
Active Trials
NCT04495582Completed8Est. Sep 2024
NCT03265444Completed9Est. Dec 2019
Biocorp
BiocorpFrance - Issoire
1 program
1
AAV2-GDNF gene therapyPhase 1Gene Therapy1 trial
Active Trials
NCT04680065Active Not Recruiting9Est. Aug 2028
AFFiRiS
AFFiRiSAustria - Vienna
1 program
1
AFFITOPE® PD01A + AdjuvantPhase 11 trial
Active Trials
NCT02270489Completed30Est. Apr 2017
Ionis Pharmaceuticals
1 program
ION464PHASE_11 trial
Active Trials
NCT04165486Recruiting40Est. Sep 2027
Parexel
ParexelMA - Boston
1 program
KM-819PHASE_21 trial
Active Trials
NCT05695378Terminated68Est. Aug 2024
Teva
TevaIsrael - Petach Tikva
1 program
TEV-56286PHASE_22 trials
Active Trials
NCT07197866Recruiting200Est. May 2029
NCT06568237Recruiting350Est. Sep 2027
Biohaven
BiohavenNEW HAVEN, CT
1 program
VerdiperstatPHASE_3Small Molecule1 trial
Active Trials
NCT03952806Completed421Est. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
LundbeckAmlenetug
BiohavenVerdiperstat
Rare Disease TherapeuticsRifampicin
TevaTEV-56286
Tiziana Life SciencesForalumab Nasal
Yoda TherapeuticsYA-101
TevaTEV-56286
Alterity TherapeuticsATH434
ParexelKM-819
Alterity TherapeuticsATH434 dose level 1
LundbeckLu AF82422
ZambonSafinamide Methanesulfonate
BiocorpAAV2-GDNF gene therapy
Ionis PharmaceuticalsION464
CorestemchemonCS10BR05

Showing 15 of 17 trials with date data

Clinical Trials (18)

Total enrollment: 1,916 patients across 18 trials

NCT06706622LundbeckAmlenetug

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

Start: Dec 2024Est. completion: Oct 2029401 patients
Phase 3Active Not Recruiting
NCT03952806BiohavenVerdiperstat

Study of BHV-3241 in Participants With Multiple System Atrophy

Start: Jul 2019Est. completion: Jun 2022421 patients
Phase 3Completed
NCT01287221Rare Disease TherapeuticsRifampicin

Study of Rifampicin in Multiple System Atrophy

Start: Mar 2011Est. completion: Jan 2013100 patients
Phase 3Terminated
NCT07197866TevaTEV-56286

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Start: Sep 2025Est. completion: May 2029200 patients
Phase 2Recruiting
NCT06868628Tiziana Life SciencesForalumab Nasal

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Start: May 2025Est. completion: Apr 20275 patients
Phase 2Recruiting
NCT06848231Yoda TherapeuticsYA-101

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

Start: Mar 2025Est. completion: Dec 202675 patients
Phase 2Recruiting
NCT06568237TevaTEV-56286

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Start: Oct 2024Est. completion: Sep 2027350 patients
Phase 2Recruiting
NCT05864365Alterity TherapeuticsATH434

A Biomarker Study of ATH434 in Participants With MSA

Start: May 2023Est. completion: Feb 202510 patients
Phase 2Completed
NCT05695378ParexelKM-819

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

Start: Feb 2023Est. completion: Aug 202468 patients
Phase 2Terminated
NCT05109091Alterity TherapeuticsATH434 dose level 1

Study of ATH434 in Participants with Multiple System Atrophy

Start: Jul 2022Est. completion: Nov 202477 patients
Phase 2Completed
NCT05104476LundbeckLu AF82422

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Start: Nov 2021Est. completion: Mar 202864 patients
Phase 2Active Not Recruiting
NCT03753763ZambonSafinamide Methanesulfonate

Safinamide for Multiple System Atrophy (MSA)

Start: Oct 2019Est. completion: Jan 202149 patients
Phase 2Completed
NCT04680065BiocorpAAV2-GDNF gene therapy

GDNF Gene Therapy for Multiple System Atrophy

Start: Oct 2023Est. completion: Aug 20289 patients
Phase 1Active Not Recruiting
NCT04165486Ionis PharmaceuticalsION464

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

Start: Jul 2022Est. completion: Sep 202740 patients
Phase 1Recruiting
NCT03265444CorestemchemonCS10BR05

Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy

Start: Apr 2018Est. completion: Dec 20199 patients
Phase 1Completed
NCT02270489AFFiRiSAFFITOPE® PD01A + Adjuvant

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

Start: Dec 2014Est. completion: Apr 201730 patients
Phase 1Completed
NCT07531433Alterity TherapeuticsATH434

Post-Trial Access to ATH434 for Patients With Multiple System Atrophy

N/AAvailable
NCT04495582CorestemchemonLong-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)

Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)

Start: Aug 2018Est. completion: Sep 20248 patients
N/ACompleted

Related Jobs

Employee Experience Specialist

AskBioAskBio
Durham, NC (Hybrid)
2w ago

Process Engineer II

AskBioAskBio
Durham, NC (Onsite)
2w ago
$116K - $175K/yr

Director, Sourcing and Procurement

AskBioAskBio
Durham, NC (Hybrid)
3w ago
$171K - $280K/yr

Scientist II, Bioassay, Analytical Sciences

AskBioAskBio
Durham, NC (Onsite)
3w ago
$84K - $151K/yr

Associate Director, Regulatory Affairs, CMC

AskBioAskBio
Remote
4w ago
$155K - $266K/yr

Scientist I, Analytical Development Biochemistry

AskBioAskBio
Durham, NC (Onsite)
1mo ago
$84K - $151K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 actively recruiting trials targeting 1,916 patients
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.